The importance of presurgical somatostatin analogue therapy in acromegaly

Annamaria Colao

Vol 58, No 4 (2007)

Review paper

Submitted: 2013-02-15

Published online: 2007-05-17

View PDF

Download PDF file

Get Citation

The importance of presurgical somatostatin analogue therapy in acromegaly

Annamaria Colao

Endokrynol Pol 2007;58(4):356-360.

Vol 58, No 4 (2007)

Reviews — Postgraduate Education

Submitted: 2013-02-15

Published online: 2007-05-17

Abstract

Different types of treatment, including surgery, medical therapy and radiotherapy, are possible in achieving control of acromegaly. Of the medical therapies available, somatostatin analogues are effective in the majority of patients and can induce pituitary tumour shrinkage. The rationale and outcome of somatostatin analogue treatment before surgery in patients with acromegaly is briefly presented. In summary, the benefits of somatostatin analogues given preoperatively should be considered carefully as optimisation of cardiovascular, respiratory and metabolic functions is clinically relevant for perioperative morbidity. Somatostatin analogues also induce significant shrinkage of GH-secreting pituitary tumours, although this does not seem to be helpful in terms of improved surgical outcome. (Pol J Endocrinol 2007; 58 (4): 356-360)